ArticleAnnals of translational medicine2023
Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer.
Hidekatsu Nakai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it